How is RYANODEX administered?
Administering RYANODEX® Administer RYANODEX® by intravenous push at a minimum dose of 1 mg/kg. If the physiologic and metabolic abnormalities of MH continue, administer additional intravenous boluses up to the maximum cumulative dosage of 10 mg/kg.
How much does RYANODEX cost?
The cost for Ryanodex intravenous powder for injection 250 mg is around $3,063 for a supply of 1 powder for injection, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.
What is the difference between dantrolene and RYANODEX?
Low-concentration high-volume dantrolene sodium products contain 3000 mg of mannitol per 20-mg dantrolene sodium vial, whereas RYANODEX® contains just 125 mg of mannitol per 250-mg vial. 16-18 Of course, the difference is much larger when considering the number of vials needed to treat a patient.
What is dantrolene an antidote for?
The first volume provides an introduction to the series and reviews three antidotes: naloxone, a specific opioid antagonist used in the treatment of opiate poisoning; flumazenil, used to reverse the sedative, anti-convulsant and muscle-relaxant effects of benzodiazepines; and dantrolene sodium, used in the treatment of …
What do you mix with RYANODEX?
How do we reconstitute RYANODEX®? RYANODEX® (dantrolene sodium) for injectable suspension should be reconstituted with 5 mL sterile water for injection (without a bacteriostatic agent). Shake the vial until RYANODEX® is mixed thoroughly (should take less than 10 seconds).
How quickly does RYANODEX work?
In the treatment of malignant hyperthermia (MH), only the RYANODEX® formulation of dantrolene sodium allows for rapid response with 1 vial, by 1 provider, in less than 1 minute.
What do you mix dantrolene with?
Each vial of dantrolene sodium for injection should be reconstituted by adding 60 mL of sterile water for injection USP (without a bacteriostatic agent), and the vial shaken for approximately 20 seconds or until the solution is clear.
How long does a patient need to be monitored for MH after intubation with succinylcholine?
A minimum period of 1.0 hour in PACU monitoring vital signs at least every 15 minutes and an additional hour in phase 2 PACU /step down unit is recommended.
What drugs treat MH?
Immediate treatment of malignant hyperthermia includes: Medication. A drug called dantrolene (Dantrium, Ryanodex, Revonto) is used to treat the reaction by stopping the release of calcium into the muscle.
What is the alternative for dantrolene?
Dantrolene Alternatives Compared
|Yes (this medicine)||Yes (this medicine)||No|
|Dosage Form(s) Available|
|Intravenous powder for injection Oral capsule||Intrathecal solution Oral tablet||Injectable powder for injection|
What is ryanodex used for?
RYANODEX ® (dantrolene sodium) for injectable suspension, for intravenous use. INDICATIONS AND USAGE RYANODEX is a skeletal muscle relaxant drug indicated for: Treatment of malignant hyperthermia in conjunction with appropriate supportive measures. (1) Prevention of malignant hyperthermia in patients at high risk.
How do you administer ryanodex to a patient with metabolic syndrome?
Administer Ryanodex by intravenous push at a minimum dose of 1 mg/kg. If the physiologic and metabolic abnormalities of MH continue, administer additional intravenous boluses up to the maximum cumulative dosage of 10 mg/kg. If the physiologic and metabolic abnormalities reappear, repeat Ryanodex dosing by intravenous push starting with 1 mg/kg.
How long does it take to administer ryanodex?
Simplified and rapid reconstitution to prepare a single vial within 10 seconds 1,4 Time to administer 2.5 mg/kg loading dose of RYANODEX® for a 100 kg patient is 1 minute compared to >22 minutes for other approved formulations 1,4 *
What is the pharmacokinetics of ryanodex?
The pharmacokinetics of RYANODEX was investigated in healthy volunteers following single-dose administration as an intravenous push over 60 seconds (dose range of 1 to 2. 5 mg/kg), via a peripheral catheter. There was a dose-proportional increase in plasma exposure of dantrolene and its metabolite, 5-hydroxydantrolene.